SIMCERE PHARMAC. GRP LTD Total Liabilities
SIMCERE PHARMAC. GRP LTD total liabilities. Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) has total liabilities worth €5.31 Billion EUR (≈ $6.21 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check SIMCERE PHARMAC. GRP LTD liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of SIMCERE PHARMAC. GRP LTD (2021–2025)
Total liabilities of SIMCERE PHARMAC. GRP LTD from 2021 to 2025. This chart illustrates how SIMCERE PHARMAC. GRP LTD's total liabilities have evolved over time, based on quarterly financial data.
SIMCERE PHARMAC. GRP LTD Competitors by Total Liabilities
The table below lists competitors of SIMCERE PHARMAC. GRP LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Sinyang Semiconductor
SHE:300236
|
China | CN¥1.70 Billion |
|
Doosan Bobcat Inc
KO:241560
|
Korea | ₩5.73 Trillion |
|
Fonciere Lyonnaise
PA:FLY
|
France | €3.19 Billion |
|
Hawkins Inc
NASDAQ:HWKN
|
USA | $467.69 Million |
|
SkyWest Inc
NASDAQ:SKYW
|
USA | $4.65 Billion |
|
Avista Corporation
NYSE:AVA
|
USA | $5.63 Billion |
|
Bank of Qingdao Co Ltd
SHE:002948
|
China | CN¥795.16 Billion |
|
CorVel Corp
NASDAQ:CRVL
|
USA | $280.84 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down SIMCERE PHARMAC. GRP LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see SIMCERE PHARMAC. GRP LTD total assets.
Liquidity & Leverage Metrics
SIMCERE PHARMAC. GRP LTD Total Liabilities Ratios Explained
SIMCERE PHARMAC. GRP LTD total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how SIMCERE PHARMAC. GRP LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual total liabilities of SIMCERE PHARMAC. GRP LTD from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €5.31 Billion ≈ $6.21 Billion |
+19.57% |
| 2024-12-31 | €4.44 Billion ≈ $5.19 Billion |
+22.33% |
| 2023-12-31 | €3.63 Billion ≈ $4.24 Billion |
-0.28% |
| 2022-12-31 | €3.64 Billion ≈ $4.26 Billion |
-1.55% |
| 2021-12-31 | €3.70 Billion ≈ $4.32 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more